Guangdong Ruishun Biotech Co., Ltd
5 clinical trials · Sponsor
◉ Watch Guangdong Ruishun Biotech Co., Ltd
| Record | Firm | Date |
|---|---|---|
| A Phase I Clinical Trial of RS001 in Patients with Relapsed/Refractory B-Cell Malignancies (NCT06894693) | Guangdong Ruishun Biotech Co., Ltd | 2025-04-01 |
| A Tolerability, Safety and Efficacy Study of RJMty19 in Subjects With Relapsed or Refractory B-NHL (NCT06314828) | Guangdong Ruishun Biotech Co., Ltd | 2024-05-20 |
| A Study of RJMty19 in Refractory Systemic Lupus Erythematosus (SLE) (NCT06340490) | Guangdong Ruishun Biotech Co., Ltd | 2024-05-15 |
| RC1012 Injection (Allo-DNT Cells) for the Prevention of Relapse in AML Patients After Allo-HSCT (NCT05858814) | Guangdong Ruishun Biotech Co., Ltd | 2023-05-04 |
| Phase I Clinical Trial of RC1012 Injection in Patients With r/r AML (NCT05471323) | Guangdong Ruishun Biotech Co., Ltd | 2021-01-14 |
Track Guangdong Ruishun Biotech Co., Ltd automatically
Every clearance here is in the API, with alerts when new ones post.